The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 745K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

9 articles for S Rosenberg


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics.EBI
Abbott Laboratories
Potent and selective non-cysteine-containing inhibitors of protein farnesyltransferase.EBI
Abbott Laboratories
Synthesis and biological evaluation of 2-indolyloxazolines as a new class of tubulin polymerization inhibitors. Discovery of A-289099 as an orally active antitumor agent.EBI
Abbott Laboratories
Pyridone-containing farnesyltransferase inhibitors: synthesis and biological evaluation.EBI
Abbott Laboratories
Synthesis and biological evaluation of 4-[(3-methyl-3H-imidazol-4-yl)-(2-phenylethynyl-benzyloxy)-methyl]-benzonitrile as novel farnesyltransferase inhibitor.EBI
Abbott Laboratories
Discovery of a Potent and Selective Covalent p300/CBP Inhibitor.EBI
Abbvie
Synthesis and biological evaluation of 4-[3-biphenyl-2-yl-1-hydroxy-1-(3-methyl-3H-imidazol-4-yl)-prop-2-ynyl]-1-yl-benzonitrile as novel farnesyltransferase inhibitor.EBI
Abbott Laboratories
Potent inhibitors of protein farnesyltransferase: heteroarenes as cysteine replacements.EBI
Abbott Laboratories
Imidazopyridazine derivatives as PI3KB inhibitorsBDB
Janssen Pharmaceutica